Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
IM Cannabis Corp. is a vertically integrated medical cannabis company operating primarily in the medical cannabis industry, with active operations in Israel and Germany. The company focuses on the cultivation, production, distribution, import, and marketing of medical cannabis products, serving regulated pharmaceutical-style markets rather than the adult-use segment. Its activities span cultivation, processing, branding, and pharmacy-level distribution, positioning the company across multiple points of the medical cannabis value chain.
The company’s core revenue drivers are medical cannabis product sales in Germany, one of the largest regulated medical cannabis markets globally, and Israel, a long-established medical cannabis jurisdiction. IM Cannabis Corp. differentiates itself through vertical integration, regulatory expertise, and direct access to pharmacies and patients. The company was founded in 2008 in Israel and initially focused on local medical cannabis cultivation and distribution before expanding into European markets, particularly Germany, through acquisition-led growth. Some historical details regarding early ownership structure and initial capitalization vary slightly across public disclosures; however, the overall timeline of expansion from Israel into Europe is consistently documented.
Business Operations
IM Cannabis Corp. operates through distinct but integrated business units across its two primary markets. In Israel, operations are conducted through IMC Holdings Ltd. and Focus Medical Herbs Ltd., which manage cultivation, manufacturing, distribution, and patient engagement under Israel’s medical cannabis regulatory framework. In Germany, the company operates through Adjupharm GmbH, a pharmaceutical importer and distributor supplying medical cannabis to pharmacies nationwide.
Revenue is generated through wholesale and retail medical cannabis sales, product imports, and pharmacy distribution. The company controls cultivation assets in Israel, branded product portfolios, and pharmaceutical-grade distribution licenses in Germany. IM Cannabis Corp. does not rely on recreational cannabis markets and has no material exposure to U.S. cannabis operations, reflecting a strategy centered on federally legal, regulated medical markets. Public disclosures indicate no material joint ventures outside of its wholly owned operating subsidiaries.
Strategic Position & Investments
The company’s strategic direction emphasizes disciplined growth in regulated medical markets, operational efficiency, and margin improvement rather than rapid geographic expansion. Key initiatives include optimizing cultivation yields in Israel, expanding branded product penetration in German pharmacies, and aligning supply with evolving medical demand. The acquisition of Adjupharm GmbH represents the company’s most significant strategic investment, providing direct access to Germany’s medical cannabis distribution infrastructure.
IM Cannabis Corp. has stated its intent to remain focused on medical cannabis and pharmaceutical-grade standards, rather than diversifying into adjacent wellness or recreational sectors. While the company has evaluated additional European opportunities, publicly available filings indicate that any further expansion is subject to capital availability and regulatory clarity. Information regarding future acquisitions beyond existing subsidiaries is limited; data inconclusive based on available public sources.
Geographic Footprint
IM Cannabis Corp.’s operational footprint is concentrated in Israel and Germany, with corporate headquarters in Israel and public company listing and reporting obligations in North America. Israel serves as the company’s cultivation and product development base, supported by domestic distribution to licensed patients and institutions.
Germany represents the company’s primary international market and largest revenue contributor, leveraging one of Europe’s most developed medical cannabis frameworks. The company has no active operations in North America, Asia, or South America, and its international exposure outside Europe and Israel remains limited. Its geographic strategy prioritizes depth in existing regulated markets over broad global expansion.
Leadership & Governance
IM Cannabis Corp. is led by an executive team with experience in regulated cannabis, pharmaceuticals, and public company governance. Leadership emphasizes regulatory compliance, cost control, and sustainable participation in medical cannabis markets. The company operates under a board and executive governance structure consistent with publicly listed companies, with oversight aligned to medical and pharmaceutical standards.
Key executives include:
- Oren Shuster – Chief Executive Officer
- Ron Basile – Chief Financial Officer
- Itay Gat – Chairman of the Board
- Yossi Anghel – Director
Public disclosures consistently identify these executives as central to strategic planning and operational oversight. Specific details regarding individual leadership philosophies are not extensively detailed in public filings; however, stated corporate messaging emphasizes long-term value creation, regulatory alignment, and disciplined execution.